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Activities of alanine:glyoxylate aminotransferase in the livers of two patients with primary hyperoxaluria 
type I were substantially lower than those found in five control human livers. Detailed subcellular fractiona- 
tion of one of the hyperoxaluric livers, compared with a control liver, showed that there was a complete 
absence of peroxisomal alanine:glyoxylate aminotransferase. This enzyme deficiency explains most of the 
biochemical characteristics of the disease and means that primary hyperoxaluria type I should be added 
to the rather select list of peroxisomal disorders. 
Hyperoxaluria Alanine:glyoxylate aminotransferase Glutamate:glyoxylate aminotransferase 
Peroxisomal disorder Glyoxylate metabolism (Human) Liver pathology 
1. INTRODUCTION 
Primary hyperoxaluria type I is a rare inborn er- 
ror of metabolism caused by an accumulation of 
glyoxylate, which leads to increased synthesis and 
excretion of oxalate and glycolate. Clinically the 
disease is characterized by recurrent calcium ox- 
alate kidney stones, resulting in progressive renal 
insufficiency and death usually before the age of 
20 [l]. Numerous in vivo studies in the 1960s sug- 
gested that there might be an abnormality in the 
transamination of glyoxylate to glycine [2-41 in 
the type I disease, but the observations made in 
vitro were less clear cut [5--71. 
It was then found that the activity of 
2-oxoglutarate : glyoxylate carboligase, which was 
normal in hyperoxaluric liver mitochondria [5,8], 
was depleted in the liver supernatant fractions [9]. 
This led to the general acceptance that cytosolic 
carboligase deficiency, rather than abnormal 
transamination, was the cause of primary hyperox- 
aluria type I (11. However our recent findings 
[lO,ll], together with those of other workers 
[12,13] have cast considerable doubt on this. 
Accordingly we have reinvestigated glyoxylate 
transamination in primary hyperoxaluria type I. 
Our results suggest that the basic biochemical 
defect in the disease is the absence of peroxisomal 
alanine : glyoxylate aminotransferase. 
2. EXPERIMENTAL 
2.1. Livers 
The subcellular fractionation experiments were 
carried out on the liver of a patient with 
pyridoxine-resistant primary hyperoxaluria type I 
and a normal human liver. Clinical and other data 
concerning these livers have been described [ 111. In 
addition, total enzyme activities were measured in 
four further control livers and another type I 
hyperoxaluric liver. All the livers were homoge- 
nized in ice-cold 0.25 M sucrose by the standard 
methods [l 11. The homogenates were centrifuged 
at 600 x g for 10 min and the supernatants were 
assayed for a variety of enzymes. Samples of the 
post-nuclear supernatants of one control liver 
(no.4) and one hyperoxaluric liver (no.6) were 
fractionated on isopycnic sucrose gradients 
(1.05-1.30 g/cm’) as described (111. 
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2.2, Enzyme assays 
The following enzymes were assayed: ala- 
nine : glyoxylate aminotransferase (EC 2.6.1.44) 
[ 14,151, glutamate : glyoxylate aminotransferase 
(EC 2.6.1.4) 1141, aspartate : 2-oxoglutatate 
aminotransferase (EC 2.6.1.1) [15,16], catalase 
(EC 1.11.1.6) [ 171 and D-amino acid oxidase (EC 
1.4.3.3) [ 181. Protein was measured according to 
Lowry et al. [19]. The distribution of a wide varie- 
ty of other marker enzymes for mitochondria, 
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Fig. 1. The distribution of aminotransferases and 
~roxisomal marker enzymes from control and 
hyperoxahrric livers on sucrose gradients. (a-e) Control 
liver, (f-j) hyperoxaiuric liver. (a$) Sucrose density; 
(b,g) alanine : glyoxylate aminotransferase; (c,h) 
glutamate :glyoxylate aminotransferase; (d,i) aspartate : 
2-oxoglutarate aminotransferase; (e,j) peroxisomal 
marker enzymes, D-amino acid oxidase (- ) and 
catalase (---). Open arrow p, m, c, position of 
peroxisomal, mitochondriai and cytosolic markers, 
respectively [111. 
lysosomes and cytosol has been studied on 
duplicate sucrose gradients for livers 4 and 6, the 
results of which have been published [I 11. 
3. RESULTS 
Fractionation of a control liver post-nuclear 
supernatant on a sucrose gradient (fig. IA) showed 
that most of the alanine: glyoxylate amino- 
transferase activity was localized in the fractions 
containing most of the particulate peroxisomal 
marker enzymes, D-amino acid oxidase and 
catalase, with a peak density of 1.24-1.25 g/cm3. 
On the other hand, most of the activity of glu- 
tamate :glyoxylate aminotransferase was found at 
the top of the gradient, in the cytosolic fractions 
Ill]. Aspartate :2-oxoglutarate aminotransferase 
was split between the ~tochondri~ and cytosolic 
fractions. 
In the hyperoxamric liver (fig. lB), the distribu- 
tion of alanine :glyoxylate aminotransferase was 
completely different. Most of the activity was in 
the cytosolic fractions at the top of the gradient, 
with a much smaller peak in the mitochondrial 
fractions. Its percentage distribution closely 
paralleled that of glutamate : glyoxylate amino- 
transferase. The other enzyme distributions were 
similar to those of the control. These observations 
were consistent in two control and two hyper- 
oxaluric gradients. 
Fraction number 
Fig.2. The distribution of alanine: glyoxylate amino- 
transferase from control and hyperoxaluric livers on 
sucrose gradients. The enzyme activity in control (- - -) 
and hyperoxaluric ( -) livers is expressed as pm01 
pyruvate formed/h per mg protein loaded onto the 
gradient. 
21 
Volume 201, number 1 FEBS LETTERS May 1986 
Table 1 
Activities of various aminotransferases and peroxisomal enzymes in liver post-nuclear supernatants 
Enzyme Controls Hyperoxalurics 
assayed 
1 3 4 7 5 6 8 
AGT 1.019 1.180 2.459 1.047 1.392 0.411 0.426 
AGT* 0.830 0.711 2.046 0.844 - 0.068 0.037 
GGT 0.434 0.711 0.626 0.307 - 0.520 0.590 
AOT 25.0 40.8 56.7 27.8 36.1 34.4 25.7 
CAT 2.43 1.33 1.98 2.18 1.77 0.54 1.09 
DA0 0.133 0.276 0.122 0.043 0.099 0.066 0.123 
a Calculated AGT activity allowing for a 66% crossover f om GGT [20] 
b Average of the hyperoxaluric values as a 070 of the control values 
% of 
controlb 
29.5 
4.7 
106.8 
80.6 
42.1 
70.2 
Livers 4 and 6 were those used in the subcellular-fractionation studies. AGT, alanine:glyoxylate 
aminotransferase; GGT, glutamate : glyoxylate aminotransferase; AOT, aspartate : 2-oxoglutarate 
aminotransferase; CAT, catalase; DAO, D-amino acid oxidase 
The total activity of alanine :glyoxylate 
aminotransferase in the hyperoxaluric liver was 
only about 15% of that in the control, so that 
when its distribution was expressed as total activity 
(fig.2), it could be seen clearly that the peroxisomal 
activity had disappeared altogether, rather than 
being redistributed, leaving the cytosolic activity 
similar to that of the controls. 
One further liver from a patient with primary 
hyperoxaluria type I and four further control 
livers, all previously frozen at -7O”C, were 
assayed for total alanine :glyoxylate amino- 
transferase and a variety of other enzyme activities 
(table 1). Although the spread of the control values 
was large, there was a clearly demonstrable defi- 
ciency of alanine :glyoxylate aminotransferase in 
the hyperoxaluric livers, but little difference in the 
other enzyme activities except catalase which was 
reduced to about half of the mean control value. 
When the activity of alanine: glyoxylate amino- 
transferase was corrected for the crossover from 
glutamate : glyoxylate aminotransferase [20,21], its 
activity in hyperoxaluric livers was reduced to 
negligible proportions (table 1). Similarly the 
subcellular distribution of alanine :glyoxylate 
aminotransferase in the hyperoxaluric liver 
(fig.lB) could be almost entirely accounted for by 
the reactivity of glutamate : glyoxylate amino- 
transferase towards alanine. 
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4. DISCUSSION 
The results on the subcellular distribution of the 
aminotransferases in the control liver are compati- 
ble with the previous literature [15,22-241. 
Although apparently less peroxisomal damage was 
caused in the hyperoxaluric liver, as shown by the 
lower levels of peroxisomal markers at the top of 
the gradient, no peroxisomal alanine :glyoxylate 
aminotransferase could be found. 
In addition a marked deficiency of ala- 
nine : glyoxylate aminotransferase was also 
demonstrated in another hyperoxaluric liver, while 
no deficiencies were found in either of the other 
aminotransferases or the peroxisomal markers, ex- 
cept catalase which was somewhat lower. 
Therefore it would appear that the liver in primary 
hyperoxaluria type I is deficient specifically in 
peroxisomal alanine :glyoxylate aminotransferase 
and does not have a generalized defect in 
transamination or peroxisomes. 
Although numerous in vivo studies have shown 
the importance of transamination in the 
metabolism of glyoxylate in hyperoxaluric patients 
[2-41, in vitro studies have failed to demonstrate 
any specific or consistent transamination defect 
[3-81. The probable reason for this is that either 
the wrong enzyme (glutamate : glyoxylate amino- 
transferase) was investigated, or that the wrong 
liver fractions (mitochondria [5]; high-speed super- 
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Fig.3. Diagrammatic representation of the metabolism of peroxisomal glyoxylate. (a) Alanine:glyoxylate 
aminotransferase, thedeficient enzyme in primary hyperoxaluria type I; (2) glutamate: glyoxylate aminotransferase; (3) 
lactate dehydrogenase. 
natants [4,7]) were studied. No abnormality was 
found in these areas in this study. 
The observation that peroxisomes are missing in 
the livers of patients with Zellweger’s syndrome 
[25] has stimulated much interest in the pathology 
of these organelles. The discovery that many of the 
enzymes involved in glyoxylate synthesis and 
metabolism are located in peroxisomes has led to 
much speculation about their possible role in the 
pathology of hyperoxaluria [26-281. This work 
provides the first definite evidence for such a role. 
In normal liver glyoxylate produced in the perox- 
isomes would be irreversibly transaminated to 
glycine, using alanine as the amino donor. In type 
I hyperoxaluric liver this intraperoxisomal 
transamination would not occur. Instead the 
glyoxylate would pass through the peroxisomal 
membrane into the cytosol, where it would 
dismute, under the influence of the excess of lac- 
tate dehydrogenase to oxalate and glycolate (fig.3) 
[27,29]. The resulting overproduction of oxalate 
could cause most of the pathological symptoms of 
the disease. 
REFERENCES 
111 
121 
[31 
Williams, H.E. and Smith, L.H. (1983) in: The 
Metabolic Basis of Inherited Disease (Stanbury, 
J.B. et al. eds) pp.204-228, McGraw-Hill, New 
York. 
Frederick, E.W., Rabkin, M.T., Richie, R.H. and 
Smith, L.H. (1963) New Engl. J. Med. 269, 
821-829. 
Smith, L.H., Hockaday, T.D.R., Efron, M.L. and 
Clayton, J.E. (1964) Trans. Assoc. Am. Physicians 
77, 317-325. 
23 
Volume 201, number 1 FEBS LETTERS May 1986 
[4] Hockaday, T.D.R., Clayton, J.E. and Smith, L.H. 
(1965) Arch. Dis. Child. 40, 485-491. 
[5] Crawhall, J.C. and Watts, R.W.E. (1962) Clin. Sci. 
23, 163-168. 
[6] Dean, B.M., Watts, R.W.E. and Westwick, W.J. 
(1967) Biochem. J. 105, 701-707. 
[7] Williams, H.E., Wilson, K.M. and Smith, L.H. 
(1967) J. Lab. Clin. Med. 70, 494-502. 
[8] Crawhall, J.C. and Watts, R.W.E. (1962) 
Biochem. J. 85, 163-171. 
[9] Koch, J., Stockstad, E.L.R., Williams, H.E. and 
Smith, L.H. (1967) Proc. Natl. Acad. Sci. USA 57, 
1123-1129. 
[lo] Danpure, C.J., Purkiss, P., Jennings, P.R. and 
Watts, R.W.E. (1985) Clin. Sci. 69 (suppl.l2), 
p.45. 
[l I] Danpure, C.J., Purkiss, P., Jennings, P.R. and 
Watts, R.W.E. (1986) Clin. Sci., in press. 
[12] O’Fallon, J.V. and Brosemer, R.W. (1977) Bio- 
chim. Biophys. Acta 499, 321-328. 
[ 131 Schlossberg, M.A., Bloom, R.J., Richert, D.A. 
and Westerfield, W.W. (1970) Biochemistry 9, 
1148-1153. 
[14] Rowsell, E.V., Carnie, J.A., Snell, K. and Taktak, 
B. (1972) Int. J. Biochem. 3, 247-257. 
[15] Nakatani, T., Kawasaki, Y., Minatogawa, Y., 
Okuno, E. and Kido, R. (1985) Clin. Biochem. 18, 
311-316. 
[16] Sizer, I.W. and Jenkins, W.T. (1962) Methods 
Enzymol. 5, 677-684. 
[17] Baudhuin, P., Beaufay, H., Rahman-Li, Y., 
Sellinger, O.Z., Wattiaux, R., Jacques, P. and 
DeDuve, C. (1964) Biochem. J. 92, 179-184. 
[ 181 Wanders, R. J.A., Schutgens, R.B.H. and Tager, 
J.M. (1985) J. Inher. Metab. Dis. 8 (suppl.2), 
151-152. 
[19] Lowry, O.H., Rosebrough, N.J., Farr, A.L. and 
Randall, R.J. (1951) J. Biol. Chem. 193, 265-275. 
[20] Thompson, J.S. and Richardson, K.E. (1966) 
Arch. Biochem. Biophys. 117, 599-603. 
[21] Thompson, J.S. and Richardson, K.E. (1967) J. 
Biol. Chem. 242, 3614-3619. 
[22] Rej, R., Keese, C.R. and Giaever, I. (1981) Clin. 
Chem. 27, 1597-1601. 
[23] Cooper, A.J.L. (1985) Methods Enzymol. 113, 
66-69. 
[24] Nakada, H.I. (1964) J. Biol. Chem. 239, 468-471. 
[25] Goldfischer, S., Moore, C.L., Johnson, A.B., 
Spiro, A.J., Valsamis, M.P., Wisniewski, H.K., 
Ritch, R.H., Norton, W.T., Rapin, I. and Gartner, 
L.M. (1973) Science 182, 62-64. 
[26] Vandor, S.L. and Tolbert, N.E. (1970) Biochim. 
Biophys. Acta 215, 449-455. 
[27] Tolbert, N.E. (1978) Methods Enzymol. 52, 
493-505. 
[28] Tolbert, N.E. (1981) Annu. Rev. Biochem. 50, 
133-157. 
[29] Gibbs, D.A. and Watts, R.W.E. (1973) Clin. Sci. 
44, 227-241. 
24 
